Ignite Creation Date:
2024-05-05 @ 10:47 PM
Last Modification Date:
2024-10-26 @ 10:24 AM
Study NCT ID:
NCT01189383
Status:
COMPLETED
Last Update Posted:
2016-12-22
First Post:
2010-08-25
Brief Title:
IL15 Dendritic Cell Vaccine for Patients With Resected Stage III A B or C or Stage IV Melanoma
Sponsor:
Baylor Research Institute
Organization:
Baylor Research Institute
Study Overview
Official Title:
IL15-DC Vaccine in Patients With High Risk Melanoma - Exploratory Phase III Trial
Status:
COMPLETED
Status Verified Date:
2016-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to gather data on feasibility as well as immune and clinical efficacy of of a dendritic cell vaccine using IL15 in patients with resected stage III or stage IV melanoma
Detailed Description:
IL15 is a T cell growth factor that pre-clinical data overwhelmingly suggests could have a very important role in cancer immunotherapy A desirable property for a dendritic cell vaccine directed against cancer is the ability to efficiently prime naïve tumor associated antigen specific T cells into potent CTLs Results of studies in healthy volunteers have shown that IL15 DCs are particularly efficient at priming functional melanoma specific CD8 T cells The use of IL15 in the manufacture of the DC vaccine could result in an improved immunotherapy product
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01CA140602 | NIH | None | httpsreporternihgovquickSearchR01CA140602 |